STOCKHOLM, SE / ACCESS Newswire / July 7, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the Leerink Therapeutics Forum.

STOCKHOLM, SE / ACCESS Newswire / July 6, 2026 / Vicore Pharma Holding (STO:VICO) - Dr. Slack brings over 20 years' experience in fibrosis and respiratory translational science…

STOCKHOLM, SE / ACCESS Newswire / July 7, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential…